Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor approved for first line therapy.

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

Discover the advantages of needle-free vaccines and which companies are developing their own promising delivery solutions in ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

In recognition of World Cancer Day 2025, AstraZeneca reaffirms its commitment to advancing early detection, innovative treatments, and holistic patient care under this year’s theme, “United by Unique.

Cancer remains one of the leading causes of death globally, with delayed diagnoses and limited access to advanced care significantly contributing to poor outcomes.

CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.

The U.K. government is defending its negotiations with AstraZeneca (AZN), after the pharmaceutical company dropped a planned $558M investment ...

Wall Street falls as Trump imposes tariffs, but not as badly as feared The threat of a punishing trade war sent Wall Street ...

If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities ...

Researchers at the Johns Hopkins Kimmel Cancer Center have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune ...

AstraZeneca has retracted a planned £450 million investment in Britain, citing reduced government support as a key factor.